RSS-Feed abonnieren
DOI: 10.1055/s-0035-1554622
Impairment of Endothelial Cell Function Induced by Hemoglobin A1c and the Potential Mechanisms
Publikationsverlauf
received 25. Januar 2015
first decision 03. April 2015
accepted 07. Mai 2015
Publikationsdatum:
11. Juni 2015 (online)
![](https://www.thieme-connect.de/media/eced/201509/lookinside/thumbnails/01-2015-0036-dia_10-1055-s-0035-1554622-1.jpg)
Abstract
Objective: Hemoglobin A1c (HbA1c) concentrations reflect glycemic control and diabetic complications. However, there is little evidence supporting the pathological role of HbA1c in the development and progression of diabetic complications. We investigated the impact of HbA1c on endothelial cell function and the potential mechanisms.
Methods: The effects of HbA1c on the viability and migration of human umbilical vein endothelial cells (HUVECs) were measured by the Cell Counting Kit-8 and a wound healing scratch assay, respectively. Production of nitric oxide (NO) and reactive oxygen species was measured by the nitrate reductase colorimetric method and flow cytometry, respectively. The expression of endothelial nitric oxide synthase (eNOS) mRNA was quantitated by reverse-transcriptase PCR. The expression of eNOS, p-AMPK, and NOX4 proteins was detected by Western blot.
Results: High concentrations of HbA1c reduced the viability and migration of HUVECs in a dose- and time-dependent manner. High concentrations of HbA1c inhibited production of NO but increased production of ROS. Incubation with increasing concentrations of HbA1c downregulated the expression of eNOS mRNA, decreased expression of eNOS and p-AMPK, and upregulated expression of NOX4.
Conclusion: These findings provide direct evidence that HbA1c is involved in the development and progression of the cardiovascular complications of diabetes.
-
References
- 1 Krishnamurti U, Steffes MW. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clinical chemistry 2001; 47: 1157-1165
- 2 Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care 2004; 27: 1047-1053
- 3 Standards of medical care in diabetes–2012. Diabetes care 2012; 35 (Suppl. 01) S11-S63
- 4 Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Annals of the New York Academy of Sciences 2005; 1043: 9-19
- 5 Sacks DB. Measurement of hemoglobin A(1c): a new twist on the path to harmony. Diabetes care 2012; 35: 2674-2680
- 6 Ravid M, Brosh D, Ravid-Safran D et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Archives of internal medicine 1998; 158: 998-1004
- 7 Avogaro A, Albiero M, Menegazzo L et al. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes care 2011; 34 (Suppl. 02) S285-S290
- 8 Rajendran P, Rengarajan T, Thangavel J et al. The Vascular Endothelium and Human Diseases. International journal of biological sciences 2013; 9: 1057-1069
- 9 Vallejo S, Angulo J, Peiro C et al. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia 2000; 43: 83-90
- 10 Rodriguez-Manas L, Arribas S, Giron C et al. Interference of glycosylated human hemoglobin with endothelium-dependent responses. Circulation 1993; 88: 2111-2116
- 11 Angulo J, Sanchez-Ferrer CF, Peiro C et al. Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin. Possible mechanisms involved. Hypertension 1996; 28: 583-592
- 12 Lu J, Ji J, Meng H et al. The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovascular diabetology 2013; 12: 58
- 13 Mazière C, Floret S, Santus R et al. Impairment of the EGF signaling pathway by the oxidative stress generated with UVA. Free Radical Biology and Medicine 2003; 34: 629-636
- 14 Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends in endocrinology and metabolism: TEM 2001; 12: 225-230
- 15 Avogaro A, Fadini GP, Gallo A et al. de Kreutzenberg S. Endothelial dysfunction in type 2 diabetes mellitus. Nutrition, metabolism, and cardiovascular diseases: NMCD 2006; 16 (Suppl. 01) S39-S45
- 16 Botker HE, Moller N. ON NO–the continuing story of nitric oxide, diabetes, and cardiovascular disease. Diabetes 2013; 62: 2645-2647
- 17 Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arteriosclerosis, thrombosis, and vascular biology 2004; 24: 413-420
- 18 Hoang HH, Padgham SV, Meininger CJ. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes. Current opinion in clinical nutrition and metabolic care 2013; 16: 76-82
- 19 Conti V, Russomanno G, Corbi G et al. Adrenoreceptors and nitric oxide in the cardiovascular system. Frontiers in physiology 2013; 4: 321
- 20 Eid AA, Lee DY, Roman LJ et al. Sestrin 2 and AMPK connect hyperglycemia to Nox4-dependent endothelial nitric oxide synthase uncoupling and matrix protein expression. Molecular and cellular biology 2013; 33: 3439-3460
- 21 Zhou Y, Yan H, Guo M et al. Reactive oxygen species in vascular formation and development. Oxidative medicine and cellular longevity 2013; 2013: 374963
- 22 Guzik TJ, Mussa S, Gastaldi D et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-1662
- 23 Bitar MS, Al-Mulla F. ROS constitute a convergence nexus in the development of IGF1 resistance and impaired wound healing in a rat model of type 2 diabetes. Disease models & mechanisms 2012; 5: 375-388
- 24 Sowers JR. Insulin resistance and hypertension. American journal of physiology. Heart and circulatory physiology 2004; 286: H1597-H1602
- 25 Newsholme P, Homem De Bittencourt P, O’Hagan C et al. Exercise and possible molecular mechanisms of protection from vascular disease and diabetes: the central role of ROS and nitric oxide. Clinical science (London, England: 1979) 2010; 118: 341-349
- 26 Inoguchi T, Sonta T, Tsubouchi H et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. Journal of the American Society of Nephrology: JASN 2003; 14: S227-S232
- 27 Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945
- 28 Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. The Journal of clinical investigation 1996; 97: 1916-1923
- 29 Ushio-Fukai M, Zafari AM, Fukui T et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. The Journal of biological chemistry 1996; 271: 23317-23321
- 30 Griendling KK, Minieri CA, Ollerenshaw JD et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circulation research 1994; 74: 1141-1148
- 31 Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. The American journal of physiology 1994; 266: H2568-H2572
- 32 Petry A, Djordjevic T, Weitnauer M et al. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxidants & redox signaling 2006; 8: 1473-1484
- 33 Wang S, Song P, Zou MH. AMP-activated protein kinase, stress responses and cardiovascular diseases. Clinical science (London, England: 1979) 2012; 122: 555-573
- 34 Levine YC, Li GK, Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK -> Rac1 -> Akt -> endothelial nitric-oxide synthase pathway. The Journal of biological chemistry 2007; 282: 20351-20364
- 35 Wang S, Zhang M, Liang B et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circulation research 2010; 106: 1117-1128
- 36 Morrow VA, Foufelle F, Connell JM et al. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. The Journal of biological chemistry 2003; 278: 31629-31639
- 37 Hurley RL, Barre LK, Wood SD et al. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. The Journal of biological chemistry 2006; 281: 36662-36672
- 38 Colombo SL, Moncada S. AMPKalpha1 regulates the antioxidant status of vascular endothelial cells. The Biochemical journal 2009; 421: 163-169